Hadasit Bio-Holdings (HBL) is a publicly traded subsidiary of Hadasit Ltd, the technology transfer company of the Hadassah University Hospital in Jerusalem.

It was founded and floated on the Tel Aviv Stock Exchange and recently on the OTC (OTCBB) in order to allow public participation in the highly promising field of biotechnology.

HBL focuses on funding its portfolio companies execution of phase 1 and preparation for phase 2.

Success in either of these stages can multiply the valuation of each company up to 10 times for each milestone.HBL enables public investment in companies based on intellectual property generated by the Hadassah University Hospital, which is responsible for the majority of Israels hospital-based translational research.

In addition to public holdings (35%), including major Israeli institutional investors, HBL is held by Hadasit (23%), Centures Investments (27%), and LifeMapSciences (15%).The traded stock provides investment exposure to a select cluster of six biotechnology companies based on inventions developed and owned by Hadassah University.